Mechanism of action
MOTS-c is encoded in a short open reading frame of the mitochondrial 12S rRNA gene. In cell-culture and animal models the peptide interferes with the folate-methionine cycle; the reported inhibition of this pathway leads to accumulation of AICAR, an endogenous activator of AMP-activated protein kinase (AMPK). Through this AMPK axis the same models describe effects on cellular glucose uptake, GLUT4 translocation and the switch between glucose and fatty-acid oxidation (Lee et al., 2015). Under metabolic stress such as glucose restriction or oxidative load, MOTS-c translocates from the mitochondrion into the nucleus and binds antioxidant response elements (ARE), where it co-regulates the expression of stress-adaptive genes together with transcription factors including NRF2 and ATF1 (Kim et al., 2018). MOTS-c is additionally described as an exercise-induced peptide whose levels rise in skeletal muscle and plasma after physical activity. These observations concern the pathway level and establish no therapeutic effect.
State of evidence
The evidence base is overwhelmingly preclinical. In vitro work has characterized AMPK activation, effects on the folate-methionine cycle and nuclear translocation under metabolic stress (Lee et al., 2015; Kim et al., 2018). Rodent studies describe effects on glucose homeostasis, insulin resistance and fat mass under high-calorie feeding, and in aged mice effects on physical capacity and muscle homeostasis (Reynolds et al., 2021). Human data so far are almost entirely observational: studies have measured endogenous MOTS-c levels, for example the rise after acute exercise (Reynolds et al., 2021) or the correlation of serum concentration with muscle-strength parameters in a small preliminary study (Domin et al., 2023). No randomized, placebo-controlled trials of administered MOTS-c in humans have been published; there are no phase 2 or phase 3 data and no regulatory approval. Human pharmacokinetics remain largely uncharacterized, and assays for endogenous MOTS-c are inconsistent between studies. Whether preclinical findings translate to humans is unresolved; efficacy and safety are not established.
Storage and handling
The usual handling rules for lyophilized peptides apply: store cool, dry and protected from light in a sealed container. After reconstitution with a suitable solvent, peptide solutions are kept refrigerated in laboratory practice and used within a few days; repeated freeze-thaw cycles are generally avoided. These are generic handling notes for lyophilized peptides, not product-specific stability data.
Questions about the research
- What is MOTS-c investigated for in research?
- MOTS-c is studied as a mitochondrially encoded signaling peptide that cell and animal models link to activation of AMP-activated protein kinase (AMPK) and to the folate-methionine cycle. Research focuses on glucose metabolism, insulin sensitivity and metabolic flexibility, and on how these signals change with physical exercise and with aging. A further strand examines the peptide's translocation into the nucleus and its role in the cellular stress response.
- What is the state of the evidence on MOTS-c?
- The robust data come from cell culture and rodent models; the 2015 first description and the follow-up work on nuclear translocation and muscle homeostasis are preclinical. In humans, research has so far mainly observed endogenous MOTS-c levels, for example in relation to physical exercise or muscle strength, usually in small cohorts. Randomized controlled trials of administered MOTS-c are lacking, as are phase 2 and phase 3 data and any regulatory approval, so no statements about efficacy or safety are possible at present.
Sources
- Lee et al., Cell Metab 2015DOI: 10.1016/j.cmet.2015.02.009PMID: 25738459
- Kim et al., Cell Metab 2018DOI: 10.1016/j.cmet.2018.06.008PMID: 29983246
- Reynolds et al., Nat Commun 2021DOI: 10.1038/s41467-020-20790-0PMID: 33473109
- Domin et al., Int J Mol Sci 2023DOI: 10.3390/ijms241914951PMID: 37834399